– AMAG PHARMACEUTICALS: FDA Approves Feraheme to Treat Iron Deficiency Anemia in Adult Chronic Kidney Disease Patients – In red other strong yesterday performances – we are adding XNPT(NASDAQ) for the long term due its strong data from clinical trial TICKER BUY AREA QUOTE NOW POSITION DRIVER XNPT(NASDAQ) USD 21,85 23,2 LONG TERM CLINICAL DATA VNDA(NASDAQ) 12,1 11,8 REBUYING FANAT APPROVED CYTR(NASDAQ) USD 1,02 1,1 LONG TERM STRONG CONSENSUS JAZZ(NASDAQ) USD 4,95 3,7 LONG TERM CLINICAL DATA PARD(NASDAQ) USD 5 5,9 PROFIT TAKING(+18%) INCY(NASDAQ) USD 3,5 3,3 LONG TERM CLINICAL DATA ISTA(NASDAQ) USD 4,1 4,2 LONG TERM BEPREVE FDA APPROVAL JAV(AMEX) USD 1,3 1,25 LONG TERM STRONG CONSENSUS SLXP(NASDAQ) USD 9,9 9,9 LONG TERM STRONG CONSENSUS MAPP(NASDAQ) USD 11,3 12,3 REBUYING LONG TERM STRONG CONSENSUS ARYX(NASDAQ) USD 4,5 4,2 LONG TERM CLINICAL DATA ARRY(NASDAQ) USD 3,1 3,2 LONG TERM CLINICAL DATA GTXI(NASDAQ) USD 9,5 9,3 LONG TERM FDA ANNONCEMENT UTHR(NASDAQ) USD 84 83,4 LONG TERM FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4 5,7 LONG TERM FDA ANNONCEMENT VICL(NASDAQ) USD 3 2,7 LONG TERM SWINE FLU STAA(NASDAQ) USD 3,3 2,41 LONG TERM FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ) 7,9 8,3 LONG TERM FDA ANNONCEMENT AMAG(NASDAQ) 52,8 57,5 AH LONG TERM FDA APPROVES FERAHEME XOMA(NASDAQ) 1,2 0,82 LONG TERM NEXT DATA RELEASE HEB(AMEX) 3,3(5%OF CAPITAL) 2,25 SOLD(-35%) HEB(AMEX) was rebought after 100% gain (see old posts) MRNA(NASDAQ) 3,3 1,4 LONG TERM OVERSOLD RIGL(NASDAQ) USD 10 12,2 LONG TERM NEXT DATA RELEASE MITI(NASDAQ) USD 6 5 LONG TERM OVERSOLD MNKD (NASDAQ) USD 8,3 8,3 LONG TERM AFRESA SVNT (NASDAQ) USD 7,10 14 SHORT TERM KRYSTEXXA APPROVAL NPSP (NASDAQ) 3,1 USD 4,7 LONG TERM STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD 2,6 LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26) PROFIT TAKED(+45%) LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8) PROFIT TAKED(+80%) FANAT CLDA (NASDAQ) 15,7 USD 11 LONG TERM OVERSOLD CTIC (NASDAQ) 2,10 USD 1,7 LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD 1,7 LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD 8,7 PROFIT TAKING(+20%) LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD 12,1 LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2,2 LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6) 28,2 LONG TERM FAMPRIDINE-SR BDSI (NASDAQ) PROFIT TAKED 6,3 (+18%) ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27) 25 LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12) 6/12 PROFIT TAKING (+35%) SPPI(NASDAQ) 5,85 USD 7,4 PROFIT TAKING(+28%)
Continua la lettura con la fonte di questo articolo:
Biopharma stock list: AMAG